Table 3.
Predictors of functional benefit (MELD score decrease) following antiviral therapy based on patient baseline characteristics
| Baseline parameters |
MELD decrease |
P value (univariable) | P value (multivariable3) | OR (95%CI) | |
| Yes (n = 78, 44%) | No (n = 101, 56%) | ||||
| Age (yr) | 59 ± 9 | 59 ± 9 | 0.9781 | 0.815 | 0.996 (0.961-1.032) |
| Child-Pugh A | 53 (38) | 86 (62) | 0.0062 | 0.592 | 1.327 (0.472-3.725) |
| Child-Pugh B/C | 25 (62) | 15 (38) | |||
| MELD | 10 ± 3 | 8 ± 3 | < 0.0011 | 0.082 | 1.177 (0.980-1.414) |
| Creatinine (mg/dL) | 0.8 ± 0.3 | 0.9 ± 0.8 | 0.3441 | - | - |
| Platelets (/nL) | 104 ± 56 | 126 ± 64 | 0.0141 | 0.617 | 0.998 (0.992-1.005) |
| Albumin (g/L) | 36.7 ± 5.2 | 39.9 ± 4.9 | < 0.0011 | 0.057 | 0.928 (0.860-1.002) |
| Bilirubin (mg/dL) | 1.6 ± 1.0 | 1.1 ± 0.8 | < 0.0011 | 0.739 | 1.096 (0.638-1.883) |
Data are expressed as n (%) or means ± SD (range). Baseline and follow-up data at 12 wk after the end of treatment was available for n = 179 patients.
1
t-test;
2
Chi-square-test;
3
Multivariable logistic regression.